Earnings ·
Cingulate Inc. reported financial results for the quarter ended June 30, 2026, and provided a business update on its…
CINGCingulate Inc.
Cingulate Inc. reported financial results for the quarter ended June 30, 2026, and provided a business update on its lead ADHD asset, CTx-1301. The company held $28.4 million in cash as of June 30, 2026, providing runway through mid-2027. R&D expenses decreased to $1.5 million from $2.7 million in the prior-year period, while SG&A expenses increased to $3.9 million due to commercial readiness build-out. Net loss was $5.9 million for the quarter and $15.2 million for the first half of 2026. The company continues CMC work to resubmit its NDA following a Complete Response Letter from the FDA on June 1, 2026, which cited manufacturing concerns but not safety or efficacy issues. Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to develop next-generation pharmaceutical products.